Table 1.
Patients | n (%) 268 (100%) |
---|---|
Sex | |
Female | 196 (73.1) |
Male | 72 (26.9) |
Age | |
19–59 | 156 (58.2) |
60 or more | 112 (41.8) |
mean ± sd | 55.8 ± 13 |
Diagnostic | |
Psoriatic arthritis only | 63 (23.6) |
Rheumatoid arthritis only | 196 (73.1) |
RA+PsA | 9 (3.3) |
Comorbidity* | |
None | 130 (48.5) |
1 or more | 138 (51.5) |
Psoriasis | 52 (37.7) |
Cardiovascular | 61(44.2) |
Metabolic | 34 (24.6) |
Skeletal muscle | 35 (25.4) |
Others | 28 (20.3) |
Duration use of biologic agents (months) | |
6 – 12 | 40 (14.9) |
13 – 36 | 133 (49.6) |
37 or more | 95 (35.4) |
mean ± sd | 35.7 ± 20 |
Health care | |
Private | 56 (20.9) |
Public | 212 (79.1) |
Concomitant use of drugs with biologic agent | |
None | 81 (30.2) |
1 | 73 (27.2) |
2 or more | 114 (42.6) |
DMARD used with biologic agent | |
metrotexate | 57 (21.3) |
corticosteroids | 24 (8.9) |
Others | 64 (23.9) |
Time since diagnostic of disease RA/PSAR | |
<1 years | 5 (1.9) |
1–3 years | 9 (3.3) |
3–5 years | 31 (11.6) |
>6 years | 223 (83.2) |
*Patients may have more than one comorbidity.
PsA, Psoriatic arthritis; RA, rheumatoid arthritis.